X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Merck Ltd with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs ACTAVIS (US) - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 MERCK LTD   ACTAVIS
EQUITY SHARE DATA
    MERCK LTD
Dec-16
ACTAVIS
Dec-14
MERCK LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,06017,533-   
Low Rs62310,695-   
Sales per share (Unadj.) Rs632.43,157.2-  
Earnings per share (Unadj.) Rs45.7-394.0-  
Cash flow per share (Unadj.) Rs62.3289.7-  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.86,847.8-  
Shares outstanding (eoy) m16.60265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.5 29.8%   
Avg P/E ratio x18.4-35.8 -51.4%  
P/CF ratio (eoy) x13.548.7 27.7%  
Price / Book Value ratio x2.22.1 105.0%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,9693,752,831 0.4%   
No. of employees `0001.621.6 7.3%   
Total wages/salary Rs m1,4870-   
Avg. sales/employee Rs Th6,631.938,865.5 17.1%   
Avg. wages/employee Rs Th939.20-   
Avg. net profit/employee Rs Th479.4-4,850.0 -9.9%   
INCOME DATA
Net Sales Rs m10,498839,495 1.3%  
Other income Rs m242-2,095 -11.6%   
Total revenues Rs m10,741837,400 1.3%   
Gross profit Rs m1,135107,845 1.1%  
Depreciation Rs m276181,781 0.2%   
Interest Rs m026,479 0.0%   
Profit before tax Rs m1,102-102,511 -1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,520 0.0%   
Tax Rs m343-5,270 -6.5%   
Profit after tax Rs m759-104,760 -0.7%  
Gross profit margin %10.812.8 84.2%  
Effective tax rate %31.15.1 605.8%   
Net profit margin %7.2-12.5 -57.9%  
BALANCE SHEET DATA
Current assets Rs m6,410442,306 1.4%   
Current liabilities Rs m8,828322,571 2.7%   
Net working cap to sales %-23.014.3 -161.5%  
Current ratio x0.71.4 52.9%  
Inventory Days Days5858 99.4%  
Debtors Days Days3866 57.9%  
Net fixed assets Rs m1,406102,511 1.4%   
Share capital Rs m1660-   
"Free" reserves Rs m6,2860-   
Net worth Rs m6,4551,820,833 0.4%   
Long term debt Rs m0954,152 0.0%   
Total assets Rs m8,8283,336,988 0.3%  
Interest coverage xNM-2.9-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.20.3 472.7%   
Return on assets %8.6-2.3 -366.4%  
Return on equity %11.8-5.8 -204.4%  
Return on capital %17.1-3.0 -567.2%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Net fx Rs m-1,6530-   
CASH FLOW
From Operations Rs m1,070144,158 0.7%  
From Investments Rs m-750-345,168 0.2%  
From Financial Activity Rs m-150193,935 -0.1%  
Net Cashflow Rs m171-7,076 -2.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare MERCK LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare MERCK LTD With: UNICHEM LAB  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  AJANTA PHARMA  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - DR. DATSONS LABS COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS